Skip to main content

Advertisement

Table 2 Frequency of various treatment-emergent comorbid events a in insured patients initiating PEG-IFN-alfa and ribavirin treatment for chronic HCV infection

From: Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study

Variable No. (%) with treatment-emergent comorbid event in the preindex period No. (%) with treatment-emergent comorbid event in the postindex period No. (%) diagnosed with a new treatment-emergent comorbid event in the postindex periodb
  (n = 1269) (n = 1269) (n = 1269)
Any treatment-related comorbid event 803 (63.3) 923 (72.7) 782 (61.6)
Blood 182 (14.3) 523 (41.2) 446 (35.2)
Anemia 147 (11.6) 461 (36.3) 371 (29.2)
Neutropenia 18 (1.42) 144 (11.4) 139 (11.0)
Thrombocytopenia 46 (3.62) 101 (7.96) 85 (6.70)
Gastrointestinal 114 (8.98) 175 (13.8) 152 (12.0)
Nausea/vomiting 78 (6.15) 124 (9.77) 106 (8.35)
Diarrhea 55 (4.33) 75 (5.91) 63 (4.96)
Endocrine 317 (25.0) 354 (27.9) 154 (12.1)
Diabetes 214 (16.9) 217 (17.1) 61 (4.81)
Hyperthyroidism 20 (1.58) 30 (2.36) 26 (2.05)
Hypothyroidism 117 (9.22) 164 (12.9) 88 (6.93)
Psychiatric 262 (20.7) 375 (29.6) 255 (20.1)
Depression 181 (14.3) 266 (21.0) 146 (11.5)
Anxiety disorders 48 (3.78) 54 (4.26) 31 (2.44)
Bipolar disorders 22 (1.73) 27 (2.13) 17 (1.34)
Insomnia 82 (6.46) 143 (11.3) 114 (8.98)
Skin and subcutaneous 59 (4.65) 119 (9.38) 111 (8.75)
Alopecia 11 (0.87) 17 (1.34) 15 (1.18)
Skin rash 49 (3.86) 103 (8.12) 97 (7.64)
Other disorders 383 (30.2) 423 (33.3) 311 (24.5)
Dyspnea 91 (7.17) 98 (7.72) 76 (5.99)
Fatigue 270 (21.3) 319 (25.1) 208 (16.4)
Headache 96 (7.57) 100 (7.88) 75 (5.91)
  1. HCV, hepatitis C virus; PEG-IFN-alfa, pegylated interferon alpha.
  2. aICD-9-CM diagnosis code for listed events appearing in any diagnosis field.
  3. bEvent appears during period when patient is being treated but not in pretreatment period.